Frank Zwerner, DO
Family Medicine · Brazil, INNPI 1821254269
Payments from drug & device makers
Across 145 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$438
- Novo Nordisk$418
- Lilly USA, LLC$191
- AbbVie$169
- GSK$142
- Novartis$137
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,51597%
- Education$653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $438 |
| Novo Nordisk | 25 | $418 |
| Lilly USA, LLC | 11 | $191 |
| AbbVie | 10 | $169 |
| GSK | 9 | $142 |
| Novartis | 6 | $137 |
| Exact Sciences | 7 | $129 |
| Boehringer Ingelheim | 6 | $112 |
| Bayer | 6 | $105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $102 |
| Phathom Pharmaceuticals, Inc. | 5 | $88 |
| Amgen | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Merck | 3 | $41 |
| Abbott | 2 | $40 |
| Mylan Specialty L.p. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $33 |
| Biogen | 1 | $27 |
| Pfizer | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Harmony Biosciences LLC | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Organon | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$2,580 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 178 | $159,477 |
| MounjaroTirzepatide | 122 | $140,350 |
| OzempicSemaglutide | 121 | $113,335 |
| EliquisApixaban | 73 | $79,717 |
| JanuviaSitagliptin Phosphate | 61 | $73,123 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $65,059 |
| RybelsusSemaglutide | 27 | $39,587 |
| FarxigaDapagliflozin Propanediol | 25 | $25,126 |
| XareltoRivaroxaban | 16 | $17,845 |
| MyrbetriqMirabegron | 21 | $16,845 |
| EntrestoSacubitril/Valsartan | 37 | $16,777 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $15,852 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $13,849 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $13,104 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $112 | $173,326189 claims |
| Novo NordiskOzempic, Rybelsus | $418 | $152,921148 claims |
| Lilly USA, LLCMounjaro, Humalog | $191 | $145,739136 claims |
| MerckJanuvia, Janumet | $41 | $82,63172 claims |
| PfizerEliquis, Paxlovid | $24 | $82,42587 claims |
| GSKTrelegy Ellipta, Shingrix | $142 | $69,082105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $438 | $37,14344 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $16,84521 claims |
| NovartisEntresto | $137 | $16,77737 claims |
| AbbVieLinzess, Synthroid | $169 | $12,53250 claims |
| Sanofi-aventis U.S. LLCLantus | $13 | $5,61522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Brazil
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.